A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Ensartinib | CAS 1370651-20-9 - Request Quote

Picture of Ensartinib
SZ CAT No:SZ-E141001
CAS No
1370651-20-9
Mol.F.
C26H27Cl2FN6O3
Mol.Wt.
561.4
Inv. Status
Synthesis on demand
Shipping Condition Room Temperature

Chemical Name :

Shipping Temperature :

HSN Code :

Country of Origin :

Smiles :

Usage Note:

Ensartinib is chemically 6-Amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-((3R,5S)-3,5-dimethylpiperazine-1-carbonyl)phenyl)pyridazine-3-carboxamide. Ensartinib is supplied with detailed characterization data compliant with regulatory guideline. Ensartinib can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Ensartinib.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.

Applications & Regulatory Use Cases

Buy 1370651-20-9

Purchase 1370651-20-9

Order 1370651-20-9

Enquire 1370651-20-9

price of 1370651-20-9

1370651-20-9 Supplier

1370651-20-9 Manufacturer

1370651-20-9 Exporter

buy high quality Ensartinib

Purchase Ensartinib

Ensartinib suppliers

Ensartinib manufacturers

Ensartinib price

Order Ensartinib

Enquire Ensartinib

Ensartinib cost

Ensartinib Supplier

Ensartinib Distributor

Ensartinib for Method Validation

Ensartinib Reference Standard

Ensartinib for ANDA Filing

Ensartinib for Forced Degradation Studies

Ensartinib Identification Standards

Ensartinib for DMF Filing

ℹ️

Disclaimer

SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.

SynZeal will update these details as per new developments or findings in product specifications without further notice.

,